These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 16545477)

  • 1. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation.
    Tanaka N; Imai K; Okimoto K; Ueda S; Tokunaga Y; Ibuki R; Higaki K; Kimura T
    J Control Release; 2006 May; 112(1):51-6. PubMed ID: 16545477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine.
    Tanaka N; Imai K; Okimoto K; Ueda S; Tokunaga Y; Ohike A; Ibuki R; Higaki K; Kimura T
    J Control Release; 2005 Nov; 108(2-3):386-95. PubMed ID: 16253377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting the absorption of nilvadipine from disintegration-controlled matrix tablet in dogs.
    Sakai T; Sako K; Hayashi M
    Biol Pharm Bull; 2011; 34(11):1731-6. PubMed ID: 22040887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
    Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
    Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of drug release by utilizing pH-independent matrix system comprising water soluble drug verapamil hydrochloride.
    Baviskar D; Sharma R; Jain D
    Pak J Pharm Sci; 2013 Jan; 26(1):137-44. PubMed ID: 23261739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The kinetics of nifedipine release from porous hydrophilic matrices and the pharmacokinetics in man.
    Leucuta SE
    Pharmazie; 1988 Dec; 43(12):845-8. PubMed ID: 3247376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of nifedipine-loaded coated gelatin microcapsule as a long acting oral delivery.
    Li DX; Kim JO; Oh DH; Lee WS; Hong MJ; Kang JY; Choi JS; Woo JS; Yong CS; Choi HG
    Arch Pharm Res; 2009 Jan; 32(1):127-32. PubMed ID: 19183885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and pharmacokinetic evaluation of once-daily sustained-released system of nifedipine with solid dispersion and coating techniques.
    Wei YM; Xue ZK; Wang P; Zhao L
    Arch Pharm Res; 2013 Jul; 36(7):864-73. PubMed ID: 23463334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose.
    Yi T; Wan J; Xu H; Yang X
    Eur J Pharm Sci; 2008 Aug; 34(4-5):274-80. PubMed ID: 18541418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Per-oral controlled release dosage form of theophylline using soybean protein.
    Machida Y; Tokumura T; Nagai T
    Drug Des Deliv; 1987 Feb; 1(3):187-92. PubMed ID: 3509332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers.
    Xu X; Sun M; Zhi F; Hu Y
    Int J Pharm; 2006 Mar; 310(1-2):139-45. PubMed ID: 16413710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study.
    Wonnemann M; Schug B; Anschütz M; Brendel E; De Nucci G; Blume H
    Clin Ther; 2008 Jan; 30(1):48-58. PubMed ID: 18343242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-release compression-coated core tablet containing nifedipine for chronopharmacotherapy.
    Sawada T; Kondo H; Nakashima H; Sako K; Hayashi M
    Int J Pharm; 2004 Aug; 280(1-2):103-11. PubMed ID: 15265551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with beta-cyclodextrin.
    Chowdary KP; Kamalakara RG
    Pharmazie; 2003 Oct; 58(10):721-4. PubMed ID: 14609284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and evaluation of a novel delayed-onset sustained-release system of propranolol hydrochloride.
    Feng XM; Ren Q; Zhang WZ; Shen HF; Rong ZX; Fang C; Chen HZ
    J Pharm Pharmacol; 2008 Jul; 60(7):817-22. PubMed ID: 18549667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of tegaserod maleate pH-dependent tablets.
    Zhang SQ; Thumma S; Chen GH; Deng WB; Repka MA; Li SM
    Eur J Pharm Biopharm; 2008 May; 69(1):247-54. PubMed ID: 18037278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and in vitro-in vivo evaluation of none gastric resident dipyridamole (DIP) sustained-release pellets with enhanced bioavailability.
    Xu L; Luo Y; Feng J; Xu M; Tao X; He H; Tang X
    Int J Pharm; 2012 Jan; 422(1-2):9-16. PubMed ID: 22001837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin.
    Ahmed IS; Aboul-Einien MH
    Eur J Pharm Sci; 2007 Sep; 32(1):58-68. PubMed ID: 17628451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accessibility of solid core tablet for dissolution in an asymmetric triple-layer matrix system.
    Yang L; Fassihi R
    J Pharm Pharmacol; 2003 Oct; 55(10):1331-7. PubMed ID: 14607013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.